Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ZYME | Zymeworks Inc. | 2025-10-28 16:34:15 | 19.3 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYME | 0001937653 | Zymeworks Inc. | US98985Y1082 | 894500AHOYAGYLYZJL67 | 883099146 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 108 PATRIOT DRIVE, SUITE A | MIDDLETOWN | DE | 19709 | UNITED STATES | US | 302-274-8744 | 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709 | 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709 | Zymeworks Delaware Inc. | — | 2003 | Kenneth Galbraith | 275 | http://www.zymeworks.com/ | 488,100,000 | 74,846,147 | 75,166,196 | Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. | 2025-10-23 14:22:30 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 488,100,000 | 19,600,000 | 4.1836 | 69,576,883 | -991,339 | -1.4048 |
| 2023 | 468,500,000 | 162,500,000 | 53.1046 | 70,568,222 | 6,431,294 | 10.0274 |
| 2022 | 306,000,000 | 306,000,000 | 100 | 64,136,928 | 64,136,928 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Neil Klompas | President, COO | 2023 | 321,568 | — | 468,000 | 0 | 1,007,801 | 2,125,732 |
| Christopher Astle | CFO, SVP | 2023 | 410,093 | — | 252,000 | 124,895 | 147,230 | 1,191,820 |
| Kenneth Galbraith | Chair, CEO, President | 2023 | 625,452 | — | 1,144,000 | 321,651 | 89,146 | 3,374,876 |
| Ali Tehrani | CEO, President | 2022 | 105,742 | — | 0 | 0 | 858,501 | 964,243 |
| Neil Klompas | President, COO | 2022 | 503,795 | — | 0 | 330,699 | 23,878 | 1,808,408 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 286 |
| 2023 | 277 |
| 2022 | 294 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 76,304,000 | 76,012,000 | 412,482,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 134,621,000 | 143,619,000 | 208,596,000 |
| General And Administrative Expenses | 61,506,000 | 70,446,000 | 73,358,000 |
| Operating Expenses | 213,414,000 | 214,065,000 | 281,954,000 |
| Operating Income | -137,110,000 | -138,053,000 | 130,528,000 |
| Net Income | -122,695,000 | -118,674,000 | 124,341,000 |
| Earnings Per Share Basic | -1.62 | -1.72 | 1.91 |
| Earnings Per Share Diluted | -1.62 | -1.72 | 1.9 |
| Weighted Average Shares Outstanding Basic | 75,846,681 | 68,863,010 | 65,194,775 |
| Weighted Average Shares Outstanding Diluted | 75,878,738 | 68,863,010 | 65,249,184 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 66,103,000 | 157,557,000 | 400,912,000 |
| Marketable Securities Current | — | 216,770,000 | 91,320,000 |
| Accounts Receivable | 55,815,000 | 19,477,000 | 33,400,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 300,451,000 | 412,926,000 | 544,706,000 |
| Marketable Securities Non Current | — | 82,148,000 | 886,000 |
| Property Plant And Equipment | 17,650,000 | 19,847,000 | 24,713,000 |
| Other Assets Non Current | 0 | 17,628,000 | 17,628,000 |
| Total Assets Non Current | 162,640,000 | 167,954,000 | 104,019,000 |
| Total Assets | 463,091,000 | 580,880,000 | 648,725,000 |
| Accounts Payable | 3,903,000 | 6,212,000 | 7,863,000 |
| Deferred Revenue | 25,588,000 | 3,699,000 | 2,353,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 128,000 | 1,811,000 | 840,000 |
| Total Liabilities Current | 88,294,000 | 55,763,000 | 95,625,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 923,000 | 1,701,000 | 3,101,000 |
| Total Liabilities Non Current | 36,029,000 | 60,311,000 | 60,144,000 |
| Total Liabilities | 124,323,000 | 116,074,000 | 155,769,000 |
| Common Stock | 1,015,618,000 | 997,227,000 | 886,322,000 |
| Retained Earnings | -830,335,000 | -677,437,000 | -558,763,000 |
| Accumulated Other Comprehensive Income | -6,952,000 | -6,603,000 | -6,659,000 |
| Total Shareholders Equity | 338,768,000 | 464,806,000 | 492,956,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 4,188,000 | 7,462,000 | 6,220,000 |
| Share Based Compensation Expense | 17,792,000 | 8,102,000 | 4,015,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 36,359,000 | -13,922,000 | 17,509,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 14,335,000 | -44,768,000 | 26,479,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -110,044,000 | -118,303,000 | 144,109,000 |
| Purchases Of Marketable Securities | 283,743,000 | 553,249,000 | — |
| Sales Of Marketable Securities | 325,565,000 | 350,073,000 | — |
| Acquisition Of Property Plant And Equipment | 1,991,000 | 2,474,000 | 8,150,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 38,756,000 | -207,253,000 | -53,849,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 26,233,000 | 107,534,000 |
| Repurchase Of Common Stock | 30,051,000 | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 8,857,000 | 5,006,000 | 255,000 |
| Cash From Financing Activities | -20,452,000 | 81,847,000 | 108,582,000 |
| Change In Cash | -91,454,000 | -243,355,000 | 199,045,000 |
| Cash At End Of Period | 66,103,000 | 157,557,000 | 400,912,000 |
| Income Taxes Paid | 3,179,000 | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 |
|---|---|---|
| Earnings Per Share | -1.62 | -1.72 |
| Price To Earnings Ratio | -9.037 | -6.0407 |
| Earnings Growth Rate | -5.814 | -190.0524 |
| Price Earnings To Growth Ratio | 1.5544 | 0.0318 |
| Book Value Per Share | 4.4665 | 6.7497 |
| Price To Book Ratio | 3.2777 | 1.5393 |
| Ebitda | -115,328,000 | -111,212,000 |
| Enterprise Value | — | — |
| Dividend Yield | — | — |
| Dividend Payout Ratio | — | — |
| Debt To Equity Ratio | — | — |
| Capital Expenditures | 1,991,000 | 2,596,000 |
| Free Cash Flow | -112,035,000 | -120,899,000 |
| Return On Equity | -0.3622 | -0.2553 |
| One Year Beta | 0.9261 | 0.8712 |
| Three Year Beta | 1.0072 | 0.9954 |
| Five Year Beta | 0.9378 | 0.9169 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director | 2025-08-12 | 415,000 | A | 488,500 |
| Landry Robert E | Director | 2025-08-11 | 62,000 | A | 62,000 |
| Ciongoli Gregory Austin | Director | 2025-08-11 | 62,000 | A | 62,000 |
| EcoR1 Capital, LLC | Director, 10% owner | 2025-06-26 | 5,086,480 | A | 22,970,388 |
| EcoR1 Capital, LLC | Director, 10% owner | 2025-06-26 | 41 | D | 22,970,388 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| RITHOLTZ WEALTH MANAGEMENT | 2025-09-30 | 422,252 | 24,722 | 17.08 |
| Campbell & CO Investment Adviser LLC | 2025-09-30 | 554,980 | 32,493 | 17.08 |
| Janney Montgomery Scott LLC | 2025-09-30 | 189,000 | 11,067 | 17.0778 |
| TEMA ETFS LLC | 2025-09-30 | 1,087,364 | 63,663 | 17.08 |
| NISA INVESTMENT ADVISORS, LLC | 2025-09-30 | 16,533 | 968 | 17.0795 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 40,235 | 595,880.35 | 0.0028 |
| FIDELITY COMMONWEALTH TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index ETF | ONEQ | 83,970 | 1,243,595.7 | 0.0146 |
| VANGUARD WORLD FUND | 2025-08-31 | ETF Shares | VHT | 112,546 | 1,666,806.26 | 0.0095 |
| VANGUARD WORLD FUND | 2025-08-31 | Admiral Shares | VHCIX | 112,546 | 1,666,806.26 | 0.0095 |
| VANGUARD SCOTTSDALE FUNDS | 2025-08-31 | ETF Shares | VTWO | 229,368 | 3,396,940.08 | 0.0264 |